GVR Report cover Oncology Clinical Trials Market Size, Share & Trends Report

Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional, Observational, Expanded Access), By Cancer Type, By Region, And Segment Forecasts, 2020 - 2027

  • Report ID: GVR-4-68039-139-7
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2018
  • Industry: Healthcare

Report Overview

The global oncology clinical trials market size was valued at 10.8 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 5.4% from 2020 to 2027. The market is majorly driven by the increasing number of cancer cases, the need for personalized medicines, as well as the rise in the R&D activities for oncology. Besides, increasing innovation in the field of oncology and supportive government initiatives are also driving the market for oncology clinical trials. The number of people diagnosed with cancer is expected to increase multi-fold in the coming years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Lung cancer is the leading cause of cancer death with a projected 1.8 million people diagnosed each year in the world.

U.S. clinical trials market size

Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Around 13 individuals are diagnosed with gastrointestinal stromal tumor each day. Over 60,000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Aforementioned factors are representing an increasing prevalence of cancer and a rising need for effective treatment against various types of cancers.

The research for treating cancer is moving forward at a rapid pace. A shift has been observed from chemotherapy protocols to molecularly targeted agents for immunotherapies in particular. Cancer continues to present novel challenges and opportunities for the intervention of pharmacologic. Consequently, the pharma industry continues to pursue oncology drug development at an unparalleled rate. The major trends include the evolution of clinical trials, a strong and growing pipeline of drug candidates, and sharp growth in available clinical data.

Since 1990, oncology was the industry’s largest focus on clinical drug development. This focus has continued to increase from the past several decades due to the scientific advancements in immunology, molecular biology, chemistry, cell biology, molecular, and genetics. The oncology trials continue to lead the biopharma efforts to develop new drugs. By the end of 2018, the number of compounds in the clinical development for oncology was more than twice the number of compounds in development for central nervous system disorders.

There has been an increasing number of cancer survivors living in the U.S., from 3.0 million in 1971 to 15.5 million in January 2016. Approximately 73.0% of the cancer survival gains are attributable to novel medicines. America’s biopharmaceutical research firms are developing effective and better-tolerated treatments to meet the needs of patients. An average of 85.0% of the oncology medicines in development are likely to be first-in-class. In 2018, there were 1,120 medicines and vaccines in development by America’s biopharmaceutical firms.

Phase Insights

The phase II segment led the oncology clinical trials market and accounted for more than 45.0% share in 2019. The segment is also anticipated to maintain its position over the forecast period. This is attributed to the increasing number of studies in phase II. Besides, since 2010 there has been an improvement in the overall productivity of oncology clinical trials measured as success rates relative to the trial effort by 22%. Also, by Medicines Healthcare Products Regulatory Agency (MHRA), between 2011 and 2016, the application for phase II and phase III trials grew by 5.5%.

Besides, there has been an expansion in the drug pipeline for oncology in the late-stage development by 19.0% in 2018 alone. It reached 849 in 2018 from 711 in 2019 due to the growing number of targeted therapies in the pipeline. In 2018, 91.0% of the late-stage oncology pipeline was biologic therapies and targeted small molecules. Around 711 companies are working on 849 products, with the majority from emerging biopharmaceutical companies.

Cancer Type Insights

The leukemia segment led the market for oncology clinical trials and accounted for 23.8% of the revenue share in 2019. This is attributed to the increasing number of blood cancers around the globe. New cases of blood cancer are expected to account for 10.0% of total diagnosed cases of cancer in the U.S. The statistics indicate a growing trend of blood cancer across the U.S. and the trend is similar across the globe.

In 2017, leukemia was the most common cancer in children and accounted for about 30% of all childhood cancers. As per the American Society of Clinical Oncology (ASCO), multiple myeloma is the second most common blood cancer after non-Hodgkin lymphoma in the U.S. ASCO also projected that around 32,270 U.S. adults are likely to be diagnosed with multiple myeloma in 2020, thereby projecting the need to treat them.

Study Design Insights

The interventional design segment dominated the market for oncology clinical trials with a revenue share of 87.9% in 2019. It is one of the most prominent methods used in clinical trials. Interventional studies are categorized based on the intervention that is to be studied, which includes drug or biologic, behavioral, surgical procedures, and devices. There has been a significant rise in the number of interventional studies carried out over time.

Global oncology clinical trials market share

The expanded access segment is anticipated to grow at a significant rate of 3.5% during the forecast period in the market for oncology clinical trials. Increasing innovation in clinical trial approaches is estimated to drive the segment over the forecast period. For instance, several drugs for oncology treatment are often administered to patients before the U.S. FDA approval and are considered as a part of expanded access trial.

Regional Insights

North America accounted for the largest revenue share of 55.0% in 2019 in the market for oncology clinical trials, and is expected to continue its dominance over the forecast period. This can be attributed to increasing R&D in this region, increasing adoption of new technologies in clinical research, as well as government support. For instance, the FDA has responded to the call with its adaptations in the way it reviews and approves new drugs for unmet needs of serious diseases, such as cancer. It has developed various guidelines, documents, and initiatives that aim at accelerating the development and approval of safe and effective drugs for cancer. It includes Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics; Clinical Trial Imaging Endpoint Process Standards; the FDA Accelerated Approval Program; Breakthrough Therapy; Accelerated Approval; Priority Review; and Fast Track.

Europe followed North America in terms of market share and contributed to 24.2% of the revenue share in 2019 in the market for oncology clinical trials. This is attributed to the favorable government initiatives being taken in this region. For instance, in 2015, the EMA released guidelines to accelerate the assessment of eligible medicines. In 2016, it launched the Priority Medicines (PRIME) scheme to classify those products at an early stage of development that have the potential to address unmet medical needs.

In Asia Pacific, the market for oncology clinical trials is anticipated to witness the fastest CAGR of 7.4% during the forecast period owing to the increasing availability of a large patient pool enabling easy recruitment of candidates. As per Asia Pacific’s largest expertized biotech CRO “Novotech”, the region has become a preferred destination for clinical studies due to the lower trial density, and a large number of active investigators. Many biotechnology firms seeking oncology CRO services are increasingly turning to this region.

Key Companies and Market Share Insights

The market for oncology clinical trials is highly competitive in nature. A significant factor affecting the competitive nature of the market is the quick adoption of advanced technology for improved healthcare. Also, to retain share and expand the product portfolio, major players are often involved in mergers and acquisitions along with new product launches and collaborations. For instance, in September 2019, IQVIA announced its collaboration with Cancer Researchers to advance the use of real-world evidence and expand clinical research in oncology. In June 2018, Acurian and Synexus, a part of PPD, launched SynexusPlus. SynexusPlus is a site solution for patient enrollment in clinical studies. This initiative is anticipated to improve clinical trial productivity. Some of the prominent players in the oncology clinical trials market include:

  • PAREXEL International Corporation

  • PRA Health Sciences

  • Syneos Health

  • Medpace

  • Novotech

  • Pivotal

Oncology Clinical Trials Market Report Scope

Report Attribute


Market Size value in 2020

USD 11.5 billion

Revenue forecast in 2027

USD 16.6 billion

Growth Rate

CAGR of 5.4% from 2020 to 2027

Base year for estimation


Historical data

2016 - 2018

Forecast period

2020 - 2027

Quantitative units

Revenue in USD million and CAGR from 2020 to 2027

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Phase, study design, cancer type, region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; India; Japan; China; Thailand; South Korea; Brazil; Mexico; Argentina; Colombia; South Africa; Saudi Arabia; UAE

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Key companies profiled

IQVIA; PAREXEL International Corporation; Pharmaceutical Product Development, LLC; Charles River Laboratory; ICON Plc; PRA Health Sciences; Syneos Health; Medpace; Novotech; Pivotal

Customization scope

Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2027. For the purpose of this study, Grand View Research has segmented the global oncology clinical trials market report on the basis of phase, study design, cancer type, and region:

  • Phase Outlook (Revenue, USD Million, 2016 - 2027)

    • Phase I

    • Phase II

    • Phase III

    • Phase IV

  • Study Design Outlook (Revenue, USD Million, 2016 - 2027)

    • Interventional

    • Observational

    • Expanded Access

  • Cancer Type Outlook (Revenue, USD Million, 2016 - 2027)

    • Lung cancer

    • Breast cancer

    • Thyroid cancer

    • Leukemia

    • Liver cancer

    • Skin cancer

    • Lymphoma

    • Pancreatic cancer

    • Prostate cancer

    • Colon & rectal cancer

    • Urinary system cancer

    • Other cancer

  • Regional Outlook (Revenue, USD Million, 2016 - 2027)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • India

      • Japan

      • China

      • Thailand

      • South Korea

    • Latin America

      • Brazil

      • Mexico

      • Argentina

      • Colombia

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon